Patents by Inventor Henry Wolfe
Henry Wolfe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160362444Abstract: This application is directed to the use of steroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.Type: ApplicationFiled: June 9, 2016Publication date: December 15, 2016Applicant: Ohr Pharmaceutical Inc.Inventors: Michael McLane, Inez Ruiz-White, Henry Wolfe
-
Patent number: 9365608Abstract: This application is directed to the use of steroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.Type: GrantFiled: September 8, 2008Date of Patent: June 14, 2016Assignee: Ohr Pharmaceutical, Inc.Inventors: Michael McLane, Inez Ruiz-White, Henry Wolfe
-
Publication number: 20140322302Abstract: Therapeutic peptides having guanylyl cyclase C agonist activity are disclosed. The therapeutic peptides are analogues of the E. coli STa peptide with non-natural amino acid, isosteric or D-amino acid substituents. The therapeutic peptides are useful in the treatment of chronic ideopathic constipation, inflammatory bowel disease, and other diseases. Pharmaceutical compositions comprising the therapeutic peptides are also disclosed.Type: ApplicationFiled: May 11, 2014Publication date: October 30, 2014Applicant: COMBIMAB, INCInventors: Henry Wolfe, Reinhard Ebner
-
Patent number: 8748575Abstract: Therapeutic peptides having guanylyl cyclase C agonist activity are disclosed. The therapeutic peptides are analogues of the E. coli STa peptide with non-natural amino acid, isosteric or D-amino acid substituents. The therapeutic peptides are useful in the treatment of chronic ideopathic constipation, inflammatory bowel disease, and other diseases. Pharmaceutical compositions comprising the therapeutic peptides are also disclosed.Type: GrantFiled: June 8, 2011Date of Patent: June 10, 2014Assignee: Combimab, Inc.Inventors: Henry Wolfe, Reinhard Ebner
-
Publication number: 20140038881Abstract: Therapeutic peptides having guanylyl cyclase C agonist activity are disclosed. The therapeutic peptides are analogues of the E. coli STa peptide with non-natural amino acid, isosteric or D-amino acid substituents. The therapeutic peptides are useful in the treatment of chronic ideopathic constipation, inflammatory bowel disease, and other diseases. Pharmaceutical compositions comprising comprising the therapeutic peptides are also disclosed.Type: ApplicationFiled: June 8, 2011Publication date: February 6, 2014Applicant: COMBIMAB, INCInventors: Henry Wolfe, Reinhard Ebner
-
Publication number: 20120308583Abstract: Proliferation of colorectal, gastric and esophageal cancer cells is inhibited by administering ST receptor ligand. The number of ST receptor molecules on the surface of a colorectal cell or metastasized colorectal cancer cell are increased by administering an ST receptor ligand such that ligand comes into contact with an ST receptor on the surface of the colorectal cell. Pharmaceutical compositions comprise sterile, pyrogen free ST receptor ligand and a pharmaceutically acceptable carrier or diluent. Metastasized colorectal cancer is treated or imaged by increasing the number of ST receptor molecules on the surface of a metastasized colorectal cancer cell and then administering a pharmaceutical composition containing components that target the ST receptor for delivery of a therapeutic agent or imaging agent. Methods of detecting metastasized colorectal cancer are disclosed. Methods of delivering active compounds to a colorectal cell in an individual are disclosed.Type: ApplicationFiled: June 19, 2012Publication date: December 6, 2012Applicant: Thomas Jefferson UniversityInventors: Scott A. Waldman, Giovanni Mario Pitari, Jason Park, Stephanie Schulz, Henry Wolfe, Wilhelm Lubbe
-
Publication number: 20100324004Abstract: This application is directed to the use of steroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.Type: ApplicationFiled: September 8, 2008Publication date: December 23, 2010Inventors: Michael McLane, Inez Ruiz-White, Henry Wolfe
-
Patent number: 7575891Abstract: The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, said method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and (2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.Type: GrantFiled: September 13, 2007Date of Patent: August 18, 2009Assignee: GE Healthcare ASInventors: Henry Wolfe, Fahar Merchant, Rosemina Merchant, Christopher Black, Harry Storflor, Geir Stokke, Halldis Hellebust
-
Publication number: 20080153750Abstract: The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, said method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and (2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.Type: ApplicationFiled: September 13, 2007Publication date: June 26, 2008Inventors: Henry Wolfe, Fahar Merchant, Rosemina Merchant, Christopher Black, Harry Storflor, Geir Stokke, Halldis Hellebust
-
Publication number: 20080058300Abstract: The present invention is directed to the use of compound 1436 for the induction of weight loss in an obese mammal.Type: ApplicationFiled: April 23, 2007Publication date: March 6, 2008Inventors: Michael McLane, Kristen Lantz, Susan Emeigh Hart, Andrew Albright, Hsiao-Ling Hung, Henry Wolfe
-
Patent number: 7273728Abstract: The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, the method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and (2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.Type: GrantFiled: August 15, 2005Date of Patent: September 25, 2007Assignee: GE Healthcare ASInventors: Henry Wolfe, Fahar Merchant, Rosemina Merchant, Christopher Black, Harry Storflor, Geir Stokke, Halldis Hellebust
-
Publication number: 20060222593Abstract: A peptide-chelate with affinity for the ST receptor is disclosed, wherein the chelate is tetradentate. The peptide-chelate conjugate of the invention may be labelled with a radiometal to provide a metal complex. A radiopharmaccutical composition comprising the metal complex is provided, which is suitable for the diagnostic imaging of colorectal cancer. Also provided for in the invention is a kit for the preparation of the radiopharmaceutical preparation.Type: ApplicationFiled: March 1, 2002Publication date: October 5, 2006Inventors: Alan Cuthbertson, Marivi Mendizabal, Mark Dixon, Anthony Storey, Edward Bacon, Vinay Desai, Sudahkar Kasina, Henry Wolfe
-
Publication number: 20060035340Abstract: The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, said method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and (2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.Type: ApplicationFiled: August 15, 2005Publication date: February 16, 2006Inventors: Henry Wolfe, Fahar Merchant, Rosemina Merchant, Christopher Black, Harry Storflor, Geir Stokke, Halldis Hellebust
-
Patent number: 6962803Abstract: The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, said method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and (2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.Type: GrantFiled: October 22, 2003Date of Patent: November 8, 2005Assignee: Amersham Health ASInventors: Henry Wolfe, Fahar Merchant, Rosemina Merchant, Christopher Black, Harry Storflor, Geir Stokke, Halldis Hellebust
-
Publication number: 20040258687Abstract: Proliferation of colorectal, gastric and esophageal cancer cells is inhibited by administering ST receptor ligand. The number of ST receptor molecules on the surface of a colorectal cell or metastasized colorectal cancer cell are increased by administering an ST receptor ligand such that ligand comes into contact with an ST receptor on the surface of the colorectal cell. Pharmaceutical compositions comprise sterile, pyrogen free ST receptor ligand and a pharmaceutically acceptable carrier or diluent. Metastasized colorectal cancer is treated or imaged by increasing the number of ST receptor molecules on the surface of a metastasized colorectal cancer cell and then administering a pharmaceutical composition containing components that target the ST receptor for delivery of a therapeutic agent or imaging agent. Methods of detecting metastasized colorectal cancer are disclosed. Methods of delivering active compounds to a colorectal cell in an individual are disclosed.Type: ApplicationFiled: February 10, 2004Publication date: December 23, 2004Applicant: Thomas Jefferson UniversityInventors: Scott A. Waldman, Glovanni Mario Pitari, Jason Park, Stephanie Schulz, Henry Wolfe, Wilhelm Lubbe
-
Patent number: 6749554Abstract: A medical or surgical device or tool that is designed to be implanted or inserted inside the human or mammalian body, having at least part of its surface coated whereby the ultrasound visibility of said device or tool in vivo is enhanced, wherein the coating comprises one or more of the following: (i) a matrix material containing a plurality of contrast enhancing elements; (ii) magnesium; (iii) a liquid or polymer which alters its ultrasound imaging properties upon elevating the temperature from ambient to physiological temperature; (iv) a liquid or polymer which alters its ultrasound imaging properties as a result of a change in pH; (v) an essentially non-polymeric bio-compatible compound which forms a discontinuous coating. Preferably the device or tool is a radioactive source for use in brachytherapy, and in particular a radioactive seed.Type: GrantFiled: January 11, 2002Date of Patent: June 15, 2004Assignee: Amersham PLCInventors: Robert Allen Snow, Henry Wolfe, Anna Rydbeck, Tore Gjorsvik, Steven Coffey, Hakan Malmgren, Oskar Axellson
-
Publication number: 20040087775Abstract: The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, said method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and (2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.Type: ApplicationFiled: October 22, 2003Publication date: May 6, 2004Inventors: Henry Wolfe, Fahar Merchant, Rosemina Merchant, Christopher Black, Harry Storflor, Geir Stokke, Halldis Hellebust
-
Patent number: 6689871Abstract: The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, the method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and (2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.Type: GrantFiled: January 25, 2002Date of Patent: February 10, 2004Assignee: Amersham Health ASInventors: Henry Wolfe, Fahar Merchant, Rosemina Merchant, Christopher Black, Harry Storflor, Geir Stokke, Halldis Hellebust
-
Publication number: 20020076378Abstract: The invention provides compounds comprising a linear, branched or dendrimeric polymer backbone with linked thereto at least one reporter moiety, said polymer backbone comprising a plurality of amine-containing acids. Such compounds may be linked to one or more targeting agents and are useful as therapeutic and diagnostic agents, in particular in medical imaging techniques.Type: ApplicationFiled: January 29, 2002Publication date: June 20, 2002Applicant: NYCOMED IMAGING ASInventors: Henry Wolfe, Kenneth Kellar
-
Patent number: D676565Type: GrantFiled: December 20, 2011Date of Patent: February 19, 2013Inventor: Henry Wolfe